Brahm H Segal,
Raoul Herbrecht,
David A Stevens,
Luis Ostrosky-Zeichner,
Jack Sobel,
Claudio Viscoli,
Thomas J Walsh,
Johan Maertens,
Thomas F Patterson,
John R Perfect, [......],
Maria Anna Viviani,
Jacques Bille,
Nikolaos G Almyroudis,
L Joseph Wheat, Wolfgang Graninger,
Eric J Bow,
Steven M Holland,
Bart-Jan Kullberg,
William E Dismukes,
Ben E De Pauw
[show abstract]
[hide abstract]
ABSTRACT: Invasive fungal diseases (IFDs) have become major causes of morbidity and mortality among highly immunocompromised patients. Authoritative consensus criteria to diagnose IFD have been useful in establishing eligibility criteria for antifungal trials. There is an important need for generation of consensus definitions of outcomes of IFD that will form a standard for evaluating treatment success and failure in clinical trials. Therefore, an expert international panel consisting of the Mycoses Study Group and the European Organization for Research and Treatment of Cancer was convened to propose guidelines for assessing treatment responses in clinical trials of IFDs and for defining study outcomes. Major fungal diseases that are discussed include invasive disease due to Candida species, Aspergillus species and other molds, Cryptococcus neoformans, Histoplasma capsulatum, and Coccidioides immitis. We also discuss potential pitfalls in assessing outcome, such as conflicting clinical, radiological, and/or mycological data and gaps in knowledge.
Clinical Infectious Diseases 09/2008; 47(5):674-83. · 9.15 Impact Factor
